Armentum Partners
VC Fund
San Francisco, United States
Armentum Partners is a financial services firm focused on providing debt capital raising solutions to technology and healthcare companies.
- Total investments:
- 101
- Last investment:
- Lead investor:
- 4%
Last updated:
For AI agents: llms.txt
Industries Armentum Partners invests in
Stages Armentum Partners invests in
Countries Armentum Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Post-IPO Debt
- $21M–$175M
- Debt Financing
- $10M–$65M
Investment Focus
Industry
- Health Care 45 (45%)
- Biotechnology 28 (28%)
- Medical Device 23 (23%)
- Medical 16 (16%)
- Software 10 (10%)
Stage
- Debt Financing 84 (83%)
- Post-IPO Debt 11 (11%)
- Funding Round 1 (1%)
Country
- United States 81 (80%)
- Canada 5 (5%)
- Germany 5 (5%)
- Israel 1 (1%)
- Austria 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chris Carthy
Managing Partner & Founder
|
Managing Partner & Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Groups Recover Together was founded to make treatment for opioid addiction respectful, accessible, and affordable. We empower our members to regain control of their lives through a proven, evidence-based model of medication-assisted treatment (MAT) with buprenorphine and weekly group therapy. | $55M / Debt Financing / Jan 01, 2023 | ||
| Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries andfits in the palm of a hand. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. The LUCIRA COVID-19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. | $80M / Post-IPO Debt / Feb 04, 2022 | ||
| Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases acrosstherapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis. | $175M / Post-IPO Debt / Jan 01, 2022 | ||
| KOHO Financial provides an application based banking platform intended to simplify financial products available to everyone. Its platform helps users to complete their day to day banking operations while offering tools such as goals, cash flow projections, group spending, spending insights, and categorizations, enabling users to manage theirexpenses and banking operations on the go. | $65M / Debt Financing / Jan 01, 2022 | ||
| Viome is a provider of comprehensive health insights designed to help people track their microbiome health, mitochondrial health, cellular health, and biological age. The company's insights help users to make suitable lifestyle and nutrition choices for them, enabling users to assess their internal eco-system with simple personalizedrecommendations.Viome was established on October 1, 2016 by Naveen Jain in Bellevue, Washington. | $20M / Debt Financing / Jan 01, 2022 | ||
| BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral neuropathic pain (PNP). | Debt Financing / Jan 01, 2022 | ||
| Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, andclinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. | $400M / Post-IPO Debt / Jan 01, 2022 | ||
| Apeel Sciences produces products including avocados, apples, mangos, cucumbers, and citrus protected by plants. They support the plant’s natural ability to protect against environmental stress by maintaining moisture and reducing oxidation. | $75M / Debt Financing / Jan 01, 2022 | ||
| SellerX buys and grows Amazon businesses. We are a VC-backed start-up with a growing, diversified portfolio of FBA (Fulfillment by Amazon) sellers. Our goal is to optimize and grow the brands we acquire post-acquisition.Founded by two HBS graduates: one who built an e-commerce business to $1bn+ in revenue as co-founder, and the other a formerGoldman Sachs SSG with extensive PE roll-up experience. Together, they have raised over $250mn in financing led by L Catterton, Cherry Ventures, Felix Capital, 83 North and Silicon Valley-based TriplePoint Capital. | Debt Financing / Dec 09, 2021 | ||
| Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsensemutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others.Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases. | $30M / Post-IPO Debt / Oct 05, 2021 | ||
| See all 101 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Armentum Partners invest in?
Armentum Partners invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Debt Financing and Post-IPO Debt stage. Most of the 101 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Armentum Partners invest in?
Armentum Partners typically joins rounds of $21M–$175M at Post-IPO Debt and $10M–$65M at Debt Financing. These are whole funding-round sizes, not Armentum Partners's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Armentum Partners took part in.
How do I contact Armentum Partners?
Public channels for Armentum Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Armentum Partners?
The team at Armentum Partners includes Chris Carthy (Managing Partner & Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
